# A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)

> **NCT06886659** · PHASE1 · COMPLETED · sponsor: **Incepta Pharmaceuticals Ltd** · enrollment: 80 (actual)

## Conditions studied

- Breast Cancer
- Breast Neoplasms
- Breast Disease
- Antineoplastic Agents

## Interventions

- **DRUG:** Trastuzumab (proposed Trastuzumab biosimilar)
- **DRUG:** Herclon

## Key facts

- **NCT ID:** NCT06886659
- **Lead sponsor:** Incepta Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-23
- **Primary completion:** 2024-12-28
- **Final completion:** 2024-12-28
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06886659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06886659, "A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06886659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*